This live event takes place Monday, April 6, 6 pm-8 pm EDT (3 pm-5 pm PDT).
Whether you work in recovery support, housing, or case management, or just want to learn more, this course breaks down the science in a simple, approachable way—no medical degree required. Together, we'll explore how these medications work, why they matter, and how understanding them can help reduce stigma and support long-term recovery. The goal? To equip everyone with the knowledge and confidence to be part of the solution.
This live webinar is designed for all members of the interprofessional team of professionals who want to better understand the medications used to treat opioid use disorder.
The purpose of this course is to enhance healthcare professionals' understanding of medications used in the treatment of opioid use disorder (OUD) by reviewing their mechanisms of action, clinical indications, and role within comprehensive, evidence-based treatment strategies.
Upon completion of this course, you should be able to:
- Describe the clinical differences between methadone, buprenorphine, and naltrexone, including their mechanisms of action and ideal patient profiles.
- Apply evidence-based strategies to initiate and manage medications for opioid use disorder (MOUD) in outpatient or residential settings, accounting for real-world barriers.
- Challenge common misconceptions and stigma surrounding MOUD using person-centered language and harm reduction principles.
Brooke Schaefer, MSN, MBA, FNP-C, CARN-AP, RN, lives in central Indiana with her family and runs a small homestead with a menagerie of animals. She runs CHOICE: Recovery for Mothers through Community Health Network, and is the founder of Lily Pond, a patient comfort closet, and Legacy, a continuation of CHOICE programming. She is a family nurse practitioner, a certified addictions nurse practitioner, and has an MBA.
Contributing faculty, Brooke Schaefer, MSN, MBA, FNP-C, CARN-AP, RN, has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Kimberly Byrd, EdD, PMSW
Scott Deatherage, PhD
Abimbola Farinde, PharmD, PhD
Nicholas Bertoni, MD
John Makopoulos, MD
The division planners have disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
Sarah Campbell
The Director of Development and Academic Affairs has disclosed no relevant financial relationship with any product manufacturer or service provider mentioned.
The purpose of NetCE is to provide challenging curricula to assist healthcare professionals to raise their levels of expertise while fulfilling their continuing education requirements, thereby improving the quality of healthcare.
Our contributing faculty members have taken care to ensure that the information and recommendations are accurate and compatible with the standards generally accepted at the time of publication. The publisher disclaims any liability, loss or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents. Participants are cautioned about the potential risk of using limited knowledge when integrating new techniques into practice.
It is the policy of NetCE not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.
Supported browsers for Windows include Microsoft Internet Explorer 9.0 and up, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Supported browsers for Macintosh include Safari, Mozilla Firefox 3.0 and up, Opera 9.0 and up, and Google Chrome. Other operating systems and browsers that include complete implementations of ECMAScript edition 3 and CSS 2.0 may work, but are not supported. Supported browsers must utilize the TLS encryption protocol v1.1 or v1.2 in order to connect to pages that require a secured HTTPS connection. TLS v1.0 is not supported.
The role of implicit biases on healthcare outcomes has become a concern, as there is some evidence that implicit biases contribute to health disparities, professionals' attitudes toward and interactions with patients, quality of care, diagnoses, and treatment decisions. This may produce differences in help-seeking, diagnoses, and ultimately treatments and interventions. Implicit biases may also unwittingly produce professional behaviors, attitudes, and interactions that reduce patients' trust and comfort with their provider, leading to earlier termination of visits and/or reduced adherence and follow-up. Disadvantaged groups are marginalized in the healthcare system and vulnerable on multiple levels; health professionals' implicit biases can further exacerbate these existing disadvantages.
Interventions or strategies designed to reduce implicit bias may be categorized as change-based or control-based. Change-based interventions focus on reducing or changing cognitive associations underlying implicit biases. These interventions might include challenging stereotypes. Conversely, control-based interventions involve reducing the effects of the implicit bias on the individual's behaviors. These strategies include increasing awareness of biased thoughts and responses. The two types of interventions are not mutually exclusive and may be used synergistically.
#9540L: An Overview of EMDR Therapy for Trauma-Focused Care
There is a critical and well-documented need for improved education on medications for opioid use disorder (MOUD) among healthcare professionals. Despite strong evidence supporting the use of MOUD, it remains underutilized because of stigma, provider discomfort, and lack of training. National data show that only about 11% of individuals with opioid use disorder (OUD) receive MOUD, despite it being the gold standard of care. A 2021 survey by the American Society of Addiction Medicine found that 61% of primary care providers reported feeling unprepared to manage OUD, and fewer than half had received formal training in MOUD. Additionally, research highlights the role of implicit and explicit biases that lead to reduced access and engagement. Within my organization and through national conference feedback, there is consistent demand for engaging, practical, and stigma-reducing education on MOUD delivery in both primary care and behavioral health settings. This session aims to fill these gaps through an accessible, evidence-based presentation that dispels myths, builds clinical confidence, and empowers providers to expand access to life-saving treatment.
The slides from this webinar are available here.
1. Abdel-Latif ME, Pinner J, Clews S, Cooke F, Lui K, Oei J. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics. 2006;117(6):e1163-e1169.
2. American College of Obstetricians and Gynecologists. Opioid use and opioid use disorder in pregnancy. Obstet Gynecol. 2017;130(2):e81-e394.
3. American College of Obstetricians and Gynecologists. Breastfeeding challenges and substance use disorders. Obstet Gynecol. 2021;137(2):e38-e44.
4. Becker SJ, Scott K, Helseth SA, et al. Effectiveness of medication for opioid use disorders in transition-age youth: a systematic review. J Subst Abuse Treat. 2022;132:108494.
5. Chan B, Gean E, Arkhipova-Jenkins I, et al. Retention strategies for medications for opioid use disorder in adults: a rapid evidence review. J Addict Med. 2021;15(1):74-84.
6. Fouladvand S, Talbert J, Dwoskin LP, et al. Predicting Opioid Use Disorder from Longitudinal Healthcare Data Using Multistream Transformer (MUPOD) [Preprint]. Available at http://arxiv.org/abs/2103.08800. Last accessed March 5, 2026.
8. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331.
9. Reece-Stremtan S, Marinelli KA; Academy of Breastfeeding Medicine. ABM clinical protocol #21: guidelines for breastfeeding and substance use or substance use disorder, revised 2015. Breastfeed Med. 2015;10(3):135-141.
10. Schiff DM, Nielsen T, Hoeppner BB, et al. Methadone and buprenorphine discontinuation among postpartum women with opioid use disorder. Am J Obstet Gynecol. 2021;225(5):538.e1-538.e10.
11. Substance Abuse and Mental Health Services Administration. Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder and Their Infants. Available at https://library.samhsa.gov/sites/default/files/sma18-5054.pdf. Last accessed March 5, 2026.
12. Tran TH, Griffin BL, Stone RH, Vest KM, Todd TJ. Methadone, buprenorphine, and naltrexone for the treatment of opioid use disorder in pregnant women. Pharmacotherapy. 2017;37(7):824-839.
13. Wachman EM, Byun J, Philipp BL. Breastfeeding rates among mothers of infants with neonatal abstinence syndrome. Breastfeed Med. 2010;5(4):159-164.
14. World Health Organization. Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy. Available at https://www.who.int/publications/i/item/9789241548731. Last accessed March 5, 2026.
Mention of commercial products does not indicate endorsement.